**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 8727**

**Columns:** **TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (7): Liver transplant

**Hepatic hemodynamic changes during liver transplantation: A review**

Feng AC *et al*. Hemodynamic changes during liver transplantation

An-Chieh Feng, Hsiu-Lung Fan, Teng-Wei Chen, Chung-Bao Hsieh

**An-Chieh Feng, Hsiu-Lung Fan, Teng-Wei Chen, Chung-Bao Hsieh,** Division of General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Neihu 11490, Taipei, Taiwan

**Author contributions:** Feng AC, Hsieh CB, Fan HL and Chen TW performed the research; Feng AC and Hsieh CB wrote the paper.

**Correspondence to:** **Chung-Bao Hsieh, MD,** Division of General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Rd, Sec2, Neihu 11490, Taipei, Taiwan. albert0920@yahoo.com.tw

**Telephone**: +88-69-33980018 **Fax**: +88-62-87927372

**Received:** January 3, 2014 **Revised:** March 21, 2014

**Accepted:** April 30, 2014

**Published online:**

**Abstract**

Liver transplantation is performed in the recent decades with great improvements not only technically but also conceptually. However, there is still lack of consensus about the optimal hemodynamic characteristics during liver transplantation. The representative hemodynamic parameters include portal vein pressure, portal vein flow, and hepatic venous pressure gradient; however, there are still others potential valuable parameters, such as total liver inflow and hepatic artery flow. All the parameters are correlated closely and some internal modulating mechanisms, like hepatic arterial buffer response, occur to maintain stable hepatic inflow. To distinguish the unique importance of each hepatic and systemic parameter in different states during liver transplantation, we review the published data also conducted two transplant cases with different surgical strategies applied to achieve ideal portal inflow and pressure.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Liver transplantation, hemodynamics, graft inflow modulation, liver circulation, small-for-size syndrome

**Core tip:** Even with the technical advancement of liver transplantation, there is still lack of consensus about the optimal range of the hepatic hemodynamic parameters intra-operatively. In this article, we review the physiology of liver hemodynamics in the normal population and also in the cirrhosis-related portal hypertension. The hemodynamic changes during liver transplantation with different graft types according to the primary hepatic circulation of the recipients are discussed. Finally, the flowchart applied in our center for performing graft inflow modulation according to systemic and hepatic hemodynamic parameters during liver transplantation is proposed in detail.

Feng AC, Fan HL, Chen TW, Hsieh CB. Hepatic hemodynamic changes during liver transplantation: A review. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Liver transplantation (LT) is the optimal treatment for patients with advanced-stage liver disease. However, the systemic and hepatic hemodynamic changes differ from patient to patient, such as the presence of collateral circulation, splenomegaly, or portal vein thrombus. Furthermore, the associated clinical parameters of portal vein flow (PVF), portal vein pressure (PVP), hepatic venous pressure gradient (HVPG), and hepatic artery flow (HAF) might interact, resulting in difficulties in decision making regarding whether to perform graft inflow modulation (GIM). Therefore, strategies aimed at obtaining an optimal blood supply to fulfill the oxygen and metabolic demands of the liver according to each individual represent a critical issue. In this review, we focus exclusively on the hemodynamic changes during LT and the possible correlations between clinically available parameters.

**PHYSIOLOGY OF LIVER HEMODYNAMICS**

The liver mass constitutes 2.5% of the total body weight or 33 g/kg of body weight[1,2]; however, the liver receives a total blood flow of 100-130 mL/min per 100 g liver and approximately 25% of the cardiac output[3,4]. The liver accounts for 10%-15% of the total blood volume and about 40% of that blood held in large vessels, such as the portal and hepatic veins, with the remaining 60% held in the sinusoids. Half of the hepatic blood can be rapidly expelled from the liver in response to both active and passive influences, thus providing the liver a major role as a blood volume reservoir[5,6].  
 The hepatic circulation is the most complex system among the organs owing to its dual blood supply from the portal vein and hepatic artery. The hepatic artery normally supplies about 25% of the portal blood flow to the liver, or 30 mL/minute per 100 g liver weight (LW), and provides 30%-50% of the liver oxygen requirement with well-oxygenated blood. On the other hand, the portal vein carries about 75% of the total blood flow to the liver, or 90 mL/min per 100 g of liver tissue, and offers approximately 50%-70% of the normal liver oxygen requirement with partially deoxygenated blood of the venous outflow from the entire prehepatic splanchnic vascular bed. In the resting state, the liver accounts for approximately 20% of the total oxygen consumption of the body[7].

The valveless portal vein system is low pressure, low-resistance, and regulated mainly by mesenteric and splanchnic arteriole constriction as well as intrahepatic vascular resistance. The normal PVP is 5-10 mmHg as detected by direct cannulation[8] or the splenic puncture method[9,10], and the pressure in the sinusoid bed or clinical wedge hepatic venous pressure is estimated to be higher than that of the vena cava but slightly less than that of portal vein, with values of 3-10 mmHg[7,11-15]. In contrast, the hepatic artery is a high-pressure, high-resistance system regulated intrinsically by classical arterial autoregulation with a mean pressure similar to that of the aorta[15]. The normal hepatic artery and portal vein hemodynamic supply fluctuate and compensate for each other according to the physiological condition. The well-documented interaction between the hepatic artery and portal vein is termed the hepatic arterial buffer response (HABR)[16], which involves an increase of HAF to compensate for the reduced PVF to minimize the influence of PVF changes on hepatic clearance and to maintain the overall liver blood flow and adequate oxygen supply to tissues[17-20].

However, the PVF and PVP are less strongly correlated. In the normal liver, the PVP is relatively stable even when the PVF fluctuates. The sinusoidal structure and intrahepatic vasculature comprise a compliant vascular bed that can enlarge its volume to accommodate additional portal blood flow without changes in pressure[21-25].

Normally, hepatic hemodynamics change according to the encountered physiological condition and maintain the balance between systems and physical demands; however, this homeostasis is markedly altered in liver diseases and hepatic surgeries such as LT.

**HEPATIC HEMODYNAMICS IN CIRRHOSIS-RELATED PORTAL HYPERTENSION**

Portal hypertension is defined as a sustained increase in the intraluminal pressure of the portal vein and its collaterals with a mean pressure greater than 12 mmHg, the upper limit for variceal bleeding and other clinical consequences[26]. Cirrhosis-related portal hypertension may result from initial hepatocyte injury and inflammatory necrosis; then, activated stellate cells transform into contractile, fibrogenic myofibroblasts, which produce a large amount of extracellular matrix and inflammatory cytokines, and finally excessive fibrosis[21,27]. The increased sinusoidal resistance and structural changes of the sinusoidal endothelia result in diminished PVF and a reactive increase in PVP[28-31]. In contrast, the splanchnic vasculature undergoes progressive vasodilatation due to excess of vasodilators such as nitric oxide, which is related to increased vascular sheer stress and intestinal absorption of lipopolysaccharide[22,32,33]. Subsequently, vasodilators induce progressive vasodilatation of splanchnic circulation and a related PVF increase along with the development of systemic hyperdynamic circulation with reactive splenomegaly and portosystemic collateralization in multiple locations[34-37]. However, the progressive development of the collateral network and splenomegaly vary individually; it is thought that the development of collateral circulation was due to the opening of pre-existing vascular channels in response to increased PVP[37]. In cirrhotic patients, extrahepatic shunts may account for at least 50% of the portal flow, whereas 80% of the portal flow actually reaching the liver has been observed to bypass the sinusoidal vascular bed via intrahepatic shunts[7]. The azygos blood flow has been measured using a double thermodilution catheter directed under fluoroscopy in patients with alcoholic cirrhosis. The azygos blood flow was 596 ± 78 mL/min and 305 ± 29 mL/min in patients with repeated gastroesophageal variceal bleeding and others who underwent decompressive surgery of the portal system[38].

**HEMODYNAMIC CHANGES DURING LIVER TRANSPLANTATION**

The hemodynamics vary widely among cirrhotic patients who undergo LT owing to different liver disease stages, underlying conditions, and disease nature; therefore, it quite challenging for transplant surgeons to apply individualized transplant strategies. Cirrhotic patients exhibit different hepatic and splanchnic vasculature presentations at the time of transplantation. These are divided into two major types: (1) portal vein engorgement and splenomegaly without remarkable collateral formation; and (2) shrinkage of the portal vein with massive collateralization (Figure 1A and B). The surgical strategies utilized during LT differ not only according to the vasculature but also depending on the graft type, such as a partial or full-sized graft. Thus, the hemodynamic changes during LT are important parameters for determining the optimal surgical strategy.

**LIVER TRANSPLANTATION WITH FULL-SIZED GRAFT**

Adequate blood supply to the transplanted graft is essential to graft survival and function. In full-sized grafts, it was assumed that the PVF should be at least 1000 mL/minute to maintain appropriate organ perfusion[39-41]. However, there are two major types of splanchnic vascular structures observed in patients before LT: (1) portal vein engorgement with splenomegaly but without massive collateral network formation; and (2) shrinkage of the portal vein with remarkable collateralization.

In the first situation, the possibility of developing small-for-size syndrome (SFSS) is less likely because of transplantation with a full-sized graft; however, the HABR becomes an important issue. Pratschke *et al*[42] reported that a decreased PVF of ≤ 1300 mL/min was associated with significantly lower organ survival in univariate analysis, but not in multivariate analysis; in contrast, diminished HAF was associated with an increased rate of primary nonfunction and impaired survival. In the same study, HAF was independent of other confounders with a hazard ratio of 2.5 for poor outcomes, and the clinical cutoff points of 100 mL/minute and 240 mL/minute were identified[42]. In another study, Spitzer *et al*[43] concluded that a target level of PVF > 1 L/min is required in LT to obtain better patient survival; in the hepatic artery, a baseline flow > 250 mL/minute is a minimally acceptable level, but > 400 mL/minute is ideal[43]. Therefore, when these patients undergo LT with full-sized grafts, two different types of GIM is recommended: (1) splenic artery ligation (SAL); and (2) splenectomy. We recommended that if the PVF is in the range of 1000-1300 mL/min and the HAF is < 100 mL/min, SAL may be the better choice. On the other hand, if the PVF is > 1300 mL/min and the HAF is far < 100 mL/min, splenectomy is likely the best choice if other possible structures or technical conditions are excluded. By performing SAL or splenectomy, excessive PVF can be prevented, which may impair HAF via the HABR.

In the second situation involving transplant patients with shrinkage of the portal vein and remarkable collateralization, including portal systemic shunting, the primary issue becomes the need for collateral or shunt ligation. Castillo-Suescun *et al*[44] presented a series of patients diagnosed with spontaneous splenorenal shunts (SSRSs) undergoing orthotopic LT, and shunt disconnection was performed when the post-reperfusion PVF was ≤ 1200 mL/minute without any detrimental effects on renal function. However, strong clinical evidence is lacking regarding the performance of collateral or portosystemic shunt disconnection. Because the portal vein normally carries approximately 90 mL/min per 100 g LW[7], ligation of the major collateral vessels or shunts is reasonable and required if the portal perfusion is < 1000 mL/min, as the PVF would be shunted away from the new liver by old collaterals. Margarit *et al*[45] reported two patients underwent occlusion of distal splenorenal shunt during LT with an increase of PVF similar to that of splenorenal shunts. In addition, Esquivel *et al*. reported consistent anatomic changes in the portal vein diameter according to the presence of portosystemic shunt of 1.2-1.5 cm, which was smaller compared with other adult recipients without remarkable shunting or collaterals of an average of 2.5 cm[46,47]. Therefore, it is worth noting that when the portal vein diameter is smaller preoperatively by computed tomography or intraoperatively even without obvious collateral shunting, the possibility of portal hypoperfusion should always be taken into consideration.

**LIVER TRANSPLANTATION WITH PARTIAL GRAFT**

The hemodynamic changes are even more complicated when LT with partial graft is performed because of the higher risk of SFSS. The most appropriate hemodynamic parameter in deciding the application of GIM remains a topic of debate. PVP < 15 mmHg was reported as a key factor for successful adult living donor liver transplantation (LDLT) with better two-year survival[48]. In a subsequent study conducted by the same group, the cutoff point for intentional PVP modulation was 20 mmHg, which was mainly achieved by splenectomy or additional creation of a portosystemic shunt. Finally, the authors also concluded that intentional PVP modulation at < 15 mmHg is an effective surgical strategy for small-for-size grafts that establishes greater donor safety with good LDLT results[49]. Ito *et al*. reported that an elevated PVP of > 20 mmHg early in the first week post-transplantation is strongly associated with an increased incidence of bacteremia in the first three months and worse patient (graft) survival at six months[50]. Other groups use PVP as an indicator for performing GIM, with the acceptable range of 15−20 mmHg[51,52]. The PVF is another parameter utilized by many groups; however, the proper range differs widely according to graft type. Troisi *et al*[53] reported that the optimal threshold of four times the flow rate observed in healthy donors (360 mL/min per 100 g LW) is a risk factor for graft failure, and flow rates below the target of 180 mL/minute per 100 g LW led to lower survival rates. This observation was confirmed by Hessheimer *et al*[54] in an experimental model. Shimamura *et al*[55] proposed that to avoid SFSS, a PVF of < 260 mL/min per 100 g LW is indicated. Troisi *et al*[56] also reported that a PVF value of 250 mL/min per 100 g LW predicted SFSS development.

In transplantation with partial grafts, HABR plays a crucial role despite the lack of consensus on the optimal range of HAF in LDLT. Sainz-Barriga *et al*[53] published a detailed report on the systemic and hepatic hemodynamics during LT. There was a significant difference in the median HAF between full-sized and partial grafts; however, no significant difference was found when the median HAF was indexed by graft weight. On the other hand, the ratio of PVF to HAF was elevated from the median of 6.6 to 15.4, which represented the effect of HABR[53]. Although no available data focus on the effect of the PVF to HAF ratio, it remains a potential predictor of surgical outcomes[58].

Similar to full-sized grafts, there are two major splanchnic vascular structures in patients before LT similarly as mentioned in the previous section. When the patients with engorged portal veins and splenomegaly undergo transplantation with partial grafts, the primary issue is the occurrence of SFSS. In the early era of LDLT, a graft versus recipient weight ratio (GRWR) of < 0.8 or a graft size of < 35% of the estimated standard graft weight were considered major risk factors for SFSS development[59,60]; however, with the evolution of surgical techniques and accumulation of clinical experience, the following investigations showed that the reduction of the lower limit of the GRWR to 0.6 in LDLT is safe[61-64]. The primary strategy employed to achieve better graft function and survival is strict inflow control including PVF and PVP instead of a smaller graft size. Asencio *et al*[65] hypothesized that the development of SFSS is not exclusively determined by the graft size, but instead by the hemodynamic parameters of the hepatic circulation, which indicates that hepatic hyperperfusion is a critical factor. Therefore, when cirrhotic patients with portal vein engorgement and splenomegaly undergo transplants with partial grafts, GIM is required in the majority owing to the potential risk of portal hyperperfusion. However, there is a lack of consensus about the clinical utility of using hemodynamic parameters to determine the need for and the type of GIM. It has been reported that splenic artery occlusion and coronary vein ligation can reduce the portal inflow by 52%[66], and SAL can reduce the portal inflow with a compensatory increase in HAF due to the HABR[67,68]. Troisi and de Hemptinne reported that SAL resulted in a significant decrease in the PVF from 2600 ± 832 mL/min to 1700 ± 689 mL/min and a compensatory increase in the HAF from 87 ± 39 mL to 152 ± 64 mL[56]; thus, SAL represents a simple and safe method that is sufficient to allow portal inflow modulation in most patients[69]. It is believed that intraoperative ligation of the splenic artery causes less than 50% of infarctions[70]. Furthermore, in cirrhotic patients with portal hypertension, splenic artery occlusion caused a significant reduction in PVP from the baseline of 21.5 ± 3.8 mmHg to 17.6 ± 3.2 mmHg 15 minutes after splenic artery occlusion (*P* < 0.0001) in the study conducted by Luca *et al*[71] Ito *et al*[50] reported similar results of immediate reduction of PVP with a median of 16−11 mmHg (*P* = 0.02) after SAL. Splenectomy or SAL is beneficial for improving outcomes of LDLT using a relatively smaller left lobe graft; however, splenectomy remains a life-threatening factor and is technically advanced compared with SAL[72,73]. However, Ikegami *et al*[74] began performing aggressive splenectomy using a vessel-sealing system to control PVP exceeding 20 mmHg, and a better graft survival rate was achieved compared to patients without strict portal pressure control (81.8% *vs* 90.6%, P < 0.01); in the same study, the complication rate of splenectomy was 10.1% (9/89), including pancreas leakage and overwhelming postsplenectomy sepsis[74]. Because of its technical simplicity and fewer postoperative complications, SAL can be considered the first-line GIM for portal hyperperfusion followed by subsequent splenectomy for more aggressive control[75].

Flowcharts for GIM have been proposed by different groups primarily based on PVF and PVP; the Kyoto group uses PVP ≥ 20 mmHg as the cutoff point for performing splenectomy[49]. Asencio *et al*[65] proposed that either PVP > 20 mmHg or PVF > 250 mL/min per 100 g LWis indicated for implementing PVP control maneuvers. In a more detailed algorithm, the Italy group considers a PVF value greater than four times the normal baseline value (≥ 360 mL/minute per 100 g LW) as the first-line determinant for performing portocaval shunt (PCS) or SAL, and then HVPG [HVPG = PVP − central venous pressure (CVP)] ≥ 15 mmHg is taken into consideration for possible PCS or SAL if the PVF does not exceed 4 times the normal baseline value. Finally, SAL is recommended if an HAF > 100 mL/minute can be achieved after splenic artery isolation and clump testing under a normal gradient; otherwise, there is no need for further GIM, and the use of heparin and prostacyclin is considered[53]. After summarizing the flowcharts and recommended ranges for all clinically available parameters, the algorithm currently applied in our center for GIM is primarily based on the sequence of PVF, PVP, HVPG, hepatic outflow, and finally HAF (Figure 2). Hepatic outflow obstruction may aggravate the injury caused by excessive inflow with graft congestion, and it is essential to exclude hepatic outflow obstruction as well. Currently, clinical judgment of performing GIM is mainly based on the coloration, induration, and bile production of the graft at reperfusion along with objective parameters such as PVF, PVP, or HVPG, which varies in different centers. In the algorithm applied in our center, we strongly recommend measuring all available hemodynamic parameters required for delicate and individualized surgical strategies, particularly in transplant patients at high risk for developing SFSS.

In the second situation of transplant patients with shrinkage of portal vein and remarkable collateralization receiving partial grafts, the possibility of developing SFSS is lower; however, measurement of all hemodynamic parameters remains essential for determining the need for collateral ligation. Furthermore, portal hypoperfusion can occur when the collaterals are well developed, such as SSRS or coronary veins, and this is particularly common in recipients with portal vein thrombus, an important warning sign[70]. Troisi *et al*[53] reported that flow rates below the target of 180 mL/min per 100 g LW led to lower survival rate; therefore, PVF is a major issue owing to the sinusoidal structure of the liver and its reservoir nature related to decreased PVP fluctuation if the veins are not fully distended[53,76-80]. Collateral shunting is a potential risk factor for portal hypoperfusion, and the need for disconnection remains controversial. In this circumstance, if the clinical decision is based solely the coloration and induration of the liver graft at reperfusion, the hypoperfusion state will be judged erroneously. It is worth noting that PVF measurement is required if the preoperative computed tomographic evaluations of the recipient shows a smaller portal vein caliber or the presence of remarkable collateral vessels. If the PVF is < 100 mL/min per 100 g LW, collateral ligation is definitely required, and if the PVF is between 100 to 180 mL/minute per 100 g LW, collateral vessel isolation and clump testing should be performed. If the PVF exceeds 260 mL/min per 100 g LW, ligation might not be needed to prevent portal hyperperfusion and decrease the HAF due to excessive HABR.

In order to describe the concept and rationale for GIM according to various hemodynamic parameters, we next describe two cases of LT performed in our hospital to illustrate how optimal graft inflow can be achieved.

**CASE 1**

A 49-year-old man weighing 69 kg and diagnosed with hepatitis B-related liver cirrhosis, Child-Pugh B, and a hepatocellular carcinoma of approximately 6 cm in segment four, received a 600-g right lobe liver graft from his daughter. Preoperative computed tomography showed that the portal vein was 1.8 cm in diameter and splenomegaly was present with 15.4 cm at the longest axis without remarkable collateral vessels (Figure 3A and B). After portal vein isolation, the PVF before transplantation was 972 mL/minute (162.0 mL/minute per 100 g LW) measured by a transonic flowmeter with an ultrasonic probe encircling the main portal vein. The PVP was 31 mmHg detected by the direct puncture method and the CVP level was 11 mmHg. On reperfusion, the portal inflow was 1936 mL/minute (322.7 mL/min per 100 g LW), the HAF was 93 mL/min, the PVP was 20 mmHg, and the CVP level was 7 mmHg. Considering the risk of SFSS development, SAL was performed first, and the PVF decreased to 1862 mL/min (310.3 mL/minute per 100 g LW), the HAF was 94 mL/min, the PVP was 18 mmHg, and the CVP level was 8 mmHg. The PVF remained > 260 mL/minute per 100 g LW; therefore, splenectomy was performed. After splenectomy, the PVF decreased to 1385 mL/min (230.8 mL/min per 100 g LW), the HAF increased to 115 mL/minute, the PVP was 15 mmHg, and the CVP remained at 8 mmHg with an HVPG of 7 mmHg. The postoperative course was uneventful, and the patient was discharged from the hospital eight days after the operation (Figure 4A, B and C).

**CASE 2**

A 55-year-old man weighing 89 kg with hepatitis B-related liver cirrhosis complicated by bleeding esophageal varices and a 4-cm hepatocellular carcinoma in segments six and seven underwent LDLT with a 620-g right lobe graft from his son. Preoperative computed tomography showed that the right lobe portal vein could not be identified, likely due to hepatofugal flow-induced stasis and thrombosis; splenomegaly (long axis measuring about 12.5 cm), ascites, esophageal varices, a portal-systemic shunt from the left portal vein to the left pericardiac-phrenic vein, and SSRS were also noted (Figure 5A, B and C). Before transplantation, the PVF was 136.0 mL/min (21.9 mL/min per 100 g LW), the PVP was 28 mmHg, and the CVP was 12 mmHg. At reperfusion, the PVF was 240 mL/min (38.7 mL/min per 100 g LW). Therefore, we performed hepatic artery anastomosis immediately with flow rate of 90 mL/min, and subsequent coronary vein ligation without measuring PVP because of portal hypoperfusion. Finally, the PVF was 908 mL/min (146.5 mL/min per 100 g LW), the HAF was 73.5 mL/min, the PVP was 18 mmHg, the CVP was 13 mmHg, and the HVPG was 5 mmHg. The patient recovered well after the operation and was discharged 10 d later (Figure 6A, B and C).

**DISCUSSION**

These two cases focused primarily on the two most frequently encountered situations for transplant surgeons: portal hyperperfusion and hypoperfusion. In the first case, the preoperative evaluation showed an engorged portal vein with splenomegaly, which were both considered the presentation of severe portal hypertension without well-developed collaterals, thus GIM might be required even if the GRWR was more than 0.8. We had performed a series of measurements of PVF, PVP, HAF, and CVP; the GIM of SAL and splenectomy were considered sequentially with the consideration of all hemodynamic parameters instead of PVF or PVP alone. Finally, optimal PVF, PVP, and HVPG values were achieved without difficulty. There is always a debate about the best indicator for GIM, such as PVF, PVP, or even HVPG; however, our group takes all available parameters into account and proposes an individualized transplant procedure instead.

In the second case, preoperative computed tomography revealed the presence of possible portal vein thrombus and abundant portosystemic collaterals with portal vein shrinkage, which increased the risk of the development of portal hypoperfusion after transplantation even with a smaller partial graft (GRWR < 0.8). After reperfusion, PVF measurement was performed routinely despite subjective assessment of the graft being soft without congestion, and portal hypoperfusion was noted immediately. Therefore, hepatic artery anastomosis was performed without delay with subsequent ligation of the coronary vein, which was easier and less risky than splenorenal shunt ligation. Finally, satisfying results were also obtained without surgical complications.

We strongly recommend that all hemodynamic parameters should be monitored during surgery to evaluate the graft status instead of clinical subjective observations of the graft consistency and coloration. Additionally, transplant surgeons should review the preoperative studies carefully to evaluate the possibility of portal hypoperfusion or hyperperfusion instead of considering GRWR only.

**CONCLUSION**

The delicate control of all hemodynamic parameters during LT is critical for better graft survival and a reduced risk of perioperative complications. Although a lack of consensus remains regarding the best clinical parameter such as PVF or PVP, measurement of all available hemodynamic indices is essential for developing an individualized surgical plan not based on clinical judgment alone. Preoperative evaluation of the present portal and splanchnic vasculature is warranted; in addition to graft type, surgeons can predict the likelihood of developing portal hyperperfusion or hypoperfusion states, which may lead to poor surgical outcomes. For transplant surgeons, the most challenging aspect of LT is not only the complex surgical techniques used but also the modulation of portal inflow during the operation that require comprehensive consideration of all hepatic and systemic hemodynamics both anatomically and clinically. Presently, there is a lack of statistical correlation between PVF and PVP; therefore, there is no consensus about the clinical utility of the ratio of these parameters to serve as a practical indicator for performing graft inflow modulations. Further investigation is required to identify a more generalized parameter derived from not only the hepatic but also the systemic hemodynamic status, which will represent a more reliable predictor for surgical outcomes and a potential intraoperative determinant of GIM.

**REFERENCES**

1 **WAKIM KG**. Physiology of the liver. *Am J Med* 1954; **16**: 256-271 [PMID: 13124358 DOI: 10.1016/0002-9343(54)90342-3]

2 **Wakim KG**. Basic and clinical physiology of the liver: normal and abnormal. *Anesth Analg* 1965; **44**: Suppl: 632-uppl: 710 [PMID: 5319210]

3 **BRADLEY SE**. Variations in hepatic blood flow in man during health and disease. *N Engl J Med* 1949; **240**: 456-461 [PMID: 18112686 DOI: 10.1056/NEJM194903242401203]

4 **Wade OL,** Bishop JM. Cardiac output and regional blood flow. Oxford: Blackwell, 1963

5 **Lautt WW**. Regulatory processes interacting to maintain hepatic blood flow constancy: Vascular compliance, hepatic arterial buffer response, hepatorenal reflex, liver regeneration, escape from vasoconstriction. *Hepatol Res* 2007; **37**: 891-903 [PMID: 17854463 DOI: 10.1111/j.1872-034X.2007.00148.x]

6 **Greenway CV**, Stark RD. Hepatic vascular bed. *Physiol Rev* 1971; **51**: 23-65 [PMID: 5543903]

7 **Flavio G,** Rocha. Liver blood flow: Physiology, measurement, and clinical relevance. In: Jarnagin W, editor. Blumgart's surgery of the liver, biliary tract and pancreas. Volume 1. 5th ed. Philadelphia: Saunders, 2012: 74-86

8 **Balfour DC**, Reynolds TB, levinson DC, Mikkelsen WP, Pattison AC. Hepatic vein pressure studies for evaluation of intrahepatic portal hypertension. *AMA Arch Surg* 1954; **68**: 442-447 [PMID: 13147661 DOI: 10.1001/archsurg.1954.01260050444006]

9 **ATKINSON M**, SHERLOCK S. Intrasplenic pressure as index of portal venous pressure. *Lancet* 1954; **266**: 1325-1327 [PMID: 13164385 DOI: 10.1016/S0140-6736(54)92212-6]

10 **DAVIS WD**, BATSON HM, REICHMAN S, GORLIN R, STORAASLI JP. Clinical applications of intrasplenic technique of portal pressure and hepatic blood flow determinations. *Gastroenterology* 1958; **34**: 52-64; discussion 65 [PMID: 13501355]

11 **FRIEDMAN EW**, WEINER RS. Estimation of hepatic sinusoid pressure by means of venous catheters and estimation of portal pressure by hepatic vein catheterization. *Am J Physiol* 1951; **165**: 527-531 [PMID: 14846972]

12 **KROOK H**. Estimation of portal venous pressure by occlusive hepatic vein catheterization. *Scand J Clin Lab Invest* 1953; **5**: 285-292 [PMID: 13135422 DOI: 10.3109/00365515309094199]

13 **Price JB**, Mcfate PA, Shaw RF. Dynamics of blood flow through the normal canine liver. *Surgery* 1964; **56**: 1109-1120 [PMID: 14238366]

14 **SHOEMAKER CP**. A STUDY OF HEPATIC HEMODYNAMICS IN THE DOG. *Circ Res* 1964; **15**: 216-233 [PMID: 14211803 DOI: 10.1161/01.RES.15.3.216]

15 **Eipel C**, Abshagen K, Vollmar B. Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. *World J Gastroenterol* 2010; **16**: 6046-6057 [PMID: 21182219 DOI: 10.3748/wjg.v16.i48.6046]

16 **Lautt WW**. Role and control of the hepatic artery. In: Lautt WW, editor. Hepatic circulation in health and disease. New York: Raven Press, 1981: 203-226

17 **Lautt WW**. Relationship between hepatic blood flow and overall metabolism: the hepatic arterial buffer response. *Fed Proc* 1983; **42**: 1662-1666 [PMID: 6832383]

18 **Lautt WW**, Legare DJ, Ezzat WR. Quantitation of the hepatic arterial buffer response to graded changes in portal blood flow. *Gastroenterology* 1990; **98**: 1024-1028 [PMID: 2311859 DOI: 10.1016/0016-5085(90)90029-Z]

19 **Jakab F**, Ráth Z, Schmal F, Nagy P, Faller J. The interaction between hepatic arterial and portal venous blood flows; simultaneous measurement by transit time ultrasonic volume flowmetry. *Hepatogastroenterology* 1995; **42**: 18-21 [PMID: 7782028]

20 **Lautt WW**. The hepatic artery: subservient to hepatic metabolism or guardian of normal hepatic clearance rates of humoral substances. *Gen Pharmacol* 1977; **8**: 73-78 [PMID: 340336 DOI: 10.1016/0306-3623(77)90030-1]

21 **Buob S**, Johnston AN, Webster CR. Portal hypertension: pathophysiology, diagnosis, and treatment. *J Vet Intern Med* 2011; **25**: 169-186 [PMID: 21382073 DOI: 10.1111/j.1939-1676.2011.00691.x]

22 **Iwakiri Y**, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. *Hepatology* 2006; **43**: S121-S131 [PMID: 16447289 DOI: 10.1002/hep.20993]

23 **Bosch J**, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. *J Hepatol* 2010; **53**: 558-567 [PMID: 20561700 DOI: 10.1016/j.jhep.2010.03.021]

24 **Sanyal AJ**, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. *Gastroenterology* 2008; **134**: 1715-1728 [PMID: 18471549 DOI: 10.1053/j.gastro.2008.03.007]

25 **Laleman W**, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. *Liver Int* 2005; **25**: 1079-1090 [PMID: 16343056 DOI: 10.1111/j.1478-3231.2005.01163.x]

26 **Garcia-Tsao G**, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. *Hepatology* 1985; **5**: 419-424 [PMID: 3873388 DOI: 10.1002/hep.1840050313]

27 **Gressner AM**. Hepatic fibrogenesis: the puzzle of interacting cells, fibrogenic cytokines, regulatory loops, and extracellular matrix molecules. *Z Gastroenterol* 1992; **30** Suppl 1: 5-16 [PMID: 1449018]

28 **Huet PM**, Villeneuve JP, Pomier-Layrargues G, Marleau D. Hepatic circulation in cirrhosis. *Clin Gastroenterol* 1985; **14**: 155-168 [PMID: 3886212]

29 **Rappaport AM**, MacPhee PJ, Fisher MM, Phillips MJ. The scarring of the liver acini (Cirrhosis). Tridimensional and microcirculatory considerations. *Virchows Arch A Pathol Anat Histopathol* 1983; **402**: 107-137 [PMID: 6420982 DOI: 10.1007/BF00695054]

30 **Vollmar B**, Siegmund S, Menger MD. An intravital fluorescence microscopic study of hepatic microvascular and cellular derangements in developing cirrhosis in rats. *Hepatology* 1998; **27**: 1544-1553 [PMID: 9620325 DOI: 10.1002/hep.510270612]

31 **Vollmar B**, Siegmund S, Richter S, Menger MD. Microvascular consequences of Kupffer cell modulation in rat liver fibrogenesis. *J Pathol* 1999; **189**: 85-91 [PMID: 10451493]

32 **Hennenberg M**, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. *Gut* 2008; **57**: 1300-1314 [PMID: 18445644 DOI: 10.1136/gut.2007.144584]

33 **Rasaratnam B**, Connelly N, Chin-Dusting J. Nitric oxide and the hyperdynamic circulation in cirrhosis: is there a role for selective intestinal decontamination? *Clin Sci* (Lond) 2004; **107**: 425-434 [PMID: 15270715 DOI: 10.1042/CS20040157]

34 **Zinner MJ,** Ashley SW. Chapter 47, portal hypertension, pathophysiology. In: Maingot's abdominal operations. 12th edition. Available from: URL: http: //accesssurgery.com/content.aspx?aID=57017871

35 **Bosch J**, Pizcueta P, Feu F, Fernández M, García-Pagán JC. Pathophysiology of portal hypertension. *Gastroenterol Clin North Am* 1992; **21**: 1-14 [PMID: 1568769]

36 **Groszmann RJ**. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. *Hepatology* 1994; **20**: 1359-1363 [PMID: 7927273 DOI: 10.1002/hep.1840200538]

37 **Colle I**, Geerts AM, Van Steenkiste C, Van Vlierberghe H. Hemodynamic changes in splanchnic blood vessels in portal hypertension. *Anat Rec (Hoboken)* 2008; **291**: 699-713 [PMID: 18484617 DOI: 10.1002/ar.20667]

38 **Bosch J**, Groszmann RJ. Measurement of azygos venous blood flow by a continuous thermal dilution technique: an index of blood flow through gastroesophageal collaterals in cirrhosis. *Hepatology* ; **4**: 424-429 [PMID: 6609870 DOI: 10.1002/hep.1840040312]

39 **Aucejo FN**, Hashimoto K, Quintini C, Kelly D, Vogt D, Winans C, Eghtesad B, Baker M, Fung J, Miller C. Triple-phase computed tomography and intraoperative flow measurements improve the management of portosystemic shunts during liver transplantation. *Liver Transpl* 2008; **14**: 96-99 [PMID: 18161777 DOI: 10.1002/lt.21377]

40 **Henderson JM**, Gilmore GT, Mackay GJ, Galloway JR, Dodson TF, Kutner MH. Hemodynamics during liver transplantation: the interactions between cardiac output and portal venous and hepatic arterial flows. *Hepatology* 1992; **16**: 715-718 [PMID: 1505914 DOI: 10.1002/hep.1840160316]

41 **Paulsen AW**, Klintmalm GB. Direct measurement of hepatic blood flow in native and transplanted organs, with accompanying systemic hemodynamics. *Hepatology* 1992; **16**: 100-111 [PMID: 1618464 DOI: 10.1002/hep.1840160118]

42 **Pratschke S**, Meimarakis G, Mayr S, Graeb C, Rentsch M, Zachoval R, Bruns CJ, Kleespies A, Jauch KW, Loehe F, Angele MK. Arterial blood flow predicts graft survival in liver transplant patients. *Liver Transpl* 2011; **17**: 436-445 [PMID: 21445927 DOI: 10.1002/lt.22248]

43 **Spitzer AL**, Dick AA, Bakthavatsalam R, Halldorson JB, Salvalaggio PR, Reyes JD, Perkins JD. Intraoperative portal vein blood flow predicts allograft and patient survival following liver transplantation. *HPB (Oxford)* 2010; **12**: 166-173 [PMID: 20590883 DOI: 10.1111/j.1477-2574.2009.00137.x]

44 **Castillo-Suescun F**, Oniscu GC, Hidalgo E. Hemodynamic consequences of spontaneous splenorenal shunts in deceased donor liver transplantation. *Liver Transpl* 2011; **17**: 891-895 [PMID: 21425432 DOI: 10.1002/lt.22304]

45 **Margarit C**, Lázaro JL, Charco R, Hidalgo E, Revhaug A, Murio E. Liver transplantation in patients with splenorenal shunts: intraoperative flow measurements to indicate shunt occlusion. *Liver Transpl Surg* 1999; **5**: 35-39 [PMID: 9873090 DOI: 10.1002/lt.500050114]

46 **Esquivel CO**, Klintmalm G, Iwatsuki S, Makowka L, Gordon RD, Tzakis A, Starzl TE. Liver transplantation in patients with patent splenorenal shunts. *Surgery* 1987; **101**: 430-432 [PMID: 3551166]

47 **Maillard JN**, Flamant YM, Hay JM, Chandler JG. Selectivity of the distal splenorenal shunt. *Surgery* 1979; **86**: 663-671 [PMID: 315102]

48 **Ogura Y**, Hori T, El Moghazy WM, Yoshizawa A, Oike F, Mori A, Kaido T, Takada Y, Uemoto S. Portal pressure & lt; 15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. *Liver Transpl* 2010; **16**: 718-728 [PMID: 20517905 DOI: 10.1002/lt.22059]

49 **Hori T**, Ogura Y, Ogawa K, Kaido T, Segawa H, Okajima H, Kogure T, Uemoto S. How transplant surgeons can overcome the inevitable insufficiency of allograft size during adult living-donor liver transplantation: strategy for donor safety with a smaller-size graft and excellent recipient results. *Clin Transplant* 2012; **26**: E324-E334 [PMID: 22686957 DOI: 10.1111/j.1399-0012.2012.01664.x]

50 **Ito T**, Kiuchi T, Yamamoto H, Oike F, Ogura Y, Fujimoto Y, Hirohashi K, Tanaka AK. Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications. *Transplantation* 2003; **75**: 1313-1317 [PMID: 12717222 DOI: 10.1097/01.TP.0000063707.90525.10]

51 **Wu TJ**, Dahiya D, Lee CS, Lee CF, Chou HS, Chan KM, Lee WC. Impact of portal venous hemodynamics on indices of liver function and graft regeneration after right lobe living donor liver transplantation. *Liver Transpl* 2011; **17**: 1035-1045 [PMID: 21542130 DOI: 10.1002/lt.22326]

52 **Lo CM**, Liu CL, Fan ST. Portal hyperperfusion injury as the cause of primary nonfunction in a small-for-size liver graft-successful treatment with splenic artery ligation. *Liver Transpl* 2003; **9**: 626-628 [PMID: 12783407 DOI: 10.1053/jlts.2003.50081]

53 **Sainz-Barriga M**, Scudeller L, Costa MG, de Hemptinne B, Troisi RI. Lack of a correlation between portal vein flow and pressure: toward a shared interpretation of hemodynamic stress governing inflow modulation in liver transplantation. *Liver Transpl* 2011; **17**: 836-848 [PMID: 21384528 DOI: 10.1002/lt.22295]

54 **Hessheimer AJ**, Fondevila C, Taurá P, Muñoz J, Sánchez O, Fuster J, Rimola A, García-Valdecasas JC. Decompression of the portal bed and twice-baseline portal inflow are necessary for the functional recovery of a "small-for-size" graft. *Ann Surg* 2011; **253**: 1201-1210 [PMID: 21587116 DOI: 10.1097/SLA.0b013e3181ffb2d7]

55 **Shimamura T**, Taniguchi M, Jin MB, Suzuki T, Matsushita M, Furukawa H, Todo S. Excessive portal venous inflow as a cause of allograft dysfunction in small-for-size living donor liver transplantation. *Transplant Proc* 2001; **33**: 1331 [PMID: 11267312 DOI: 10.1016/S0041-1345(00)02496-9]

56 **Troisi R**, de Hemptinne B. Clinical relevance of adapting portal vein flow in living donor liver transplantation in adult patients. *Liver Transpl* 2003; **9**: S36-S41 [PMID: 12942477 DOI: 10.1053/jlts.2003.50200]

57 **Troisi R**, Ricciardi S, Smeets P, Petrovic M, Van Maele G, Colle I, Van Vlierberghe H, de Hemptinne B. Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. *Am J Transplant* 2005; **5**: 1397-1404 [PMID: 15888047 DOI: 10.1111/j.1600-6143.2005.00850.x]

58 **Sainz-Barriga M**, Reyntjens K, Costa MG, Scudeller L, Rogiers X, Wouters P, de Hemptinne B, Troisi RI. Prospective evaluation of intraoperative hemodynamics in liver transplantation with whole, partial and DCD grafts. *Am J Transplant* 2010; **10**: 1850-1860 [PMID: 20659091 DOI: 10.1111/j.1600-6143.2010.03207.x]

59 **Kiuchi T**, Kasahara M, Uryuhara K, Inomata Y, Uemoto S, Asonuma K, Egawa H, Fujita S, Hayashi M, Tanaka K. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. *Transplantation* 1999; **67**: 321-327 [PMID: 10075602 DOI: 10.1097/00007890-199901270-00024]

60 **Fan ST**, Lo CM, Liu CL, Yong BH, Wong J. Determinants of hospital mortality of adult recipients of right lobe live donor liver transplantation. *Ann Surg* 2003; **238**: 864-69; discussion 869-70 [PMID: 14631223 DOI: 10.1097/00000658-200307000-00018]

61 **Ben-Haim M**, Emre S, Fishbein TM, Sheiner PA, Bodian CA, Kim-Schluger L, Schwartz ME, Miller CM. Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. *Liver Transpl* 2001; **7**: 948-953 [PMID: 11699030 DOI: 10.1053/jlts.2001.29033]

62 **Truant S**, Oberlin O, Sergent G, Lebuffe G, Gambiez L, Ernst O, Pruvot FR. Remnant liver volume to body weight ratio & gt; or =0.5%: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. *J Am Coll Surg* 2007; **204**: 22-33 [PMID: 17189109 DOI: 10.1016/j.jamcollsurg.2006.09.007]

63 **Selzner M**, Kashfi A, Cattral MS, Selzner N, Greig PD, Lilly L, McGilvray ID, Therapondos G, Adcock LE, Ghanekar A, Levy GA, Renner EL, Grant DR. A graft to body weight ratio less than 0.8 does not exclude adult-to-adult right-lobe living donor liver transplantation. *Liver Transpl* 2009; **15**: 1776-1782 [PMID: 19938139 DOI: 10.1002/lt.21955]

64 **Kaido T**, Mori A, Ogura Y, Hata K, Yoshizawa A, Iida T, Yagi S, Uemoto S. Lower limit of the graft-to-recipient weight ratio can be safely reduced to 0.6% in adult-to-adult living donor liver transplantation in combination with portal pressure control. *Transplant Proc* 2011; **43**: 2391-2393 [PMID: 21839274 DOI: 10.1016/j.transproceed.2011.05.037]

65 **Asencio JM**, Vaquero J, Olmedilla L, García Sabrido JL. "Small-for-flow" syndrome: shifting the "size" paradigm. *Med Hypotheses* 2013; **80**: 573-577 [PMID: 23428310 DOI: 10.1016/j.mehy.2013.01.028]

66 **Del Guercio LR**, Cohn JD, Kazarian KK, Kinkhabwalla M. A shunt equation for estimating the splenic component of portal hypertension. *Am J Surg* 1978; **135**: 70-75 [PMID: 623375 DOI: 10.1016/0002-9610(78)90012-0]

67 **Lautt WW**. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response. *Am J Physiol* 1985; **249**: G549-G556 [PMID: 3904482]

68 **Payen DM**, Fratacci MD, Dupuy P, Gatecel C, Vigouroux C, Ozier Y, Houssin D, Chapuis Y. Portal and hepatic arterial blood flow measurements of human transplanted liver by implanted Doppler probes: interest for early complications and nutrition. *Surgery* 1990; **107**: 417-427 [PMID: 2181716]

69 **Troisi R**, Cammu G, Militerno G, De Baerdemaeker L, Decruyenaere J, Hoste E, Smeets P, Colle I, Van Vlierberghe H, Petrovic M, Voet D, Mortier E, Hesse UJ, de Hemptinne B. Modulation of portal graft inflow: a necessity in adult living-donor liver transplantation? *Ann Surg* 2003; **237**: 429-436 [PMID: 12616129 DOI: 10.1097/00000658-200303000-00019]

70 **Chan SC**, Lo CM, Chok KS, Sharr WW, Cheung TT, Tsang SH, Chan AC, Fan ST. Modulation of graft vascular inflow guided by flowmetry and manometry in liver transplantation. *Hepatobiliary Pancreat Dis Int* 2011; **10**: 649-656 [PMID: 22146631 DOI: 10.1016/S1499-3872(11)60110-0]

71 **Luca A**, Miraglia R, Caruso S, Milazzo M, Gidelli B, Bosch J. Effects of splenic artery occlusion on portal pressure in patients with cirrhosis and portal hypertension. *Liver Transpl* 2006; **12**: 1237-1243 [PMID: 16741929 DOI: 10.1002/lt.20762]

72 **Shimada M**, Ijichi H, Yonemura Y, Harada N, Shiotani S, Ninomiya M, Terashi T, Yoshizumi T, Soejima Y, Suehiro T, Maehara Y. The impact of splenectomy or splenic artery ligation on the outcome of a living donor adult liver transplantation using a left lobe graft. *Hepatogastroenterology* 2004; **51**: 625-629 [PMID: 15143878]

73 **Sato Y**, Yamamoto S, Oya H, Nakatsuka H, Tsukahara A, Kobayashi T, Watanabe T, Hatakeyama K. Splenectomy for reduction of excessive portal hypertension after adult living-related donor liver transplantation. *Hepatogastroenterology* 2002; **49**: 1652-1655 [PMID: 12397756]

74 **Ikegami T**, Shirabe K, Soejima Y, Yoshizumi T, Uchiyama H, Yamashita Y, Harimoto N, Toshima T, Yoshiya S, Ikeda T, Maehara Y. Strategies for successful left-lobe living donor liver transplantation in 250 consecutive adult cases in a single center. *J Am Coll Surg* 2013; **216**: 353-362 [PMID: 23318119 DOI: 10.1016/j.jamcollsurg.2012.11.011]

75 **Ishizawa T**, Tamura S, Masuda K, Aoki T, Hasegawa K, Imamura H, Beck Y, Kokudo N. Intraoperative fluorescent cholangiography using indocyanine green: a biliary road map for safe surgery. *J Am Coll Surg* 2009; **208**: e1-e4 [PMID: 19228492 DOI: 10.1016/j.jamcollsurg.2008.09.024]

76 **Groszmann RJ**, Abraldes JG. Portal hypertension: from bedside to bench. *J Clin Gastroenterol* 2005; **39**: S125-S130 [PMID: 15758647 DOI: 10.1097/01.mcg.0000155552.14396.3d]

77 **Kroeger RJ**, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. *Hepatology* ; **5**: 97-101 [PMID: 2857150 DOI: 10.1002/hep.1840050120]

78 **Sikuler E**, Groszmann RJ. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. *Am J Physiol* 1986; **250**: G205-G212 [PMID: 3953799]

79 **Witte CL**, Tobin GR, Clark DS, Witte MH. Relationship of splanchnic blood flow and portal venous resistance to elevated portal pressure in the dog. *Gut* 1976; **17**: 122-126 [PMID: 1083352 DOI: 10.1136/gut.17.2.122]

80 **Gelman S**. Venous function and central venous pressure: a physiologic story. *Anesthesiology* 2008; **108**: 735-748 [PMID: 18362606 DOI: 10.1097/ALN.0b013e3181672607]

**P-Reviewers:** Hatipoglu S, Kaido T, Popescu I **S-Editor:** Qi Y

**L-Editor: E-Editor:**

**Figure 1 Hepatic and splanchnic vasculature at the time of transplantation in cirrhotic patients.** A: Portal vein engorgement (white arrow) and splenomegaly (white astrocyte) without remarkable collateral formation; B: Shrinkage of portal vein (white arrow head) with massive collateralization (black double astrocytes).

**Figure 2 Flowchart applied in our center for performing graft inflow modulation according to systemic and hepatic hemodynamic parameters in transplant patients with portal hyperperfusion.** Technical errors such as hepatic outflow obstruction, hepatic artery kinking, or anastomosis failure should be evaluated repeatedly. After GIM is performed, the portal vein flow (PVF), portal vein pressure (PVP), and central venous pressure should be re-measured to ensure optimal portal inflow. HAF: Hepatic artery flow; HVPG: Hepatic venous pressure gradient; LW: Liver weight.

**Figure 3 Preoperative computed tomographic findings of case 1**. A: Engorged portal vein of 1.8 cm in diameter (white arrow); B: Splenomegaly with 15.4 cm at the longest axis without remarkable collaterals (white asterisk).

**Figure 4 Sequential graft inflow modulation of case 1.** A: Splenic artery ligation (black arrow, **①**) followed with splenectomy (black arrow head, **②**); B: Sequential changes of the portal vein (PV) pressure, central venous pressure (CVP), and hepatic venous pressure gradient during liver transplantation pre- and post-GIM; C: Sequential changes of the portal vein flow (mL/minute per 100 g of LW) and hepatic artery (HA) flow (mL/minute). HVPG: Hepatic venous pressure gradient; IVC: Inferior vena cava; SpA: Splenic artery.

**Figure 5 Preoperative computed tomographic findings of case 2.** A: The right lobe portal vein could not be identified, likely owing to hepatofugal flow-induced stasis and thrombosis (white arrow head) and portal-systemic shunting from the left portal vein to the left pericardiac-phrenic vein (black asterisk); B: Coronary vein engorgement (double black asterisks); C: Spontaneous splenorenal shunting was also noted (white arrow).

**Figure 6 Sequential graft inflow modulation of case 2.** A: After transplantation with a right-lobe graft, hypoperfusion was noted and coronary vein ligation was performed immediately (black arrow); B: Sequential changes of the portal vein (PV) pressure, central venous pressure (CVP), and hepatic venous pressure gradient during liver transplantation pre- and post-coronary vein ligation; C: Sequential changes of the portal vein flow (mL/minute per 100 g of LW) and hepatic artery flow (mL/minute). Coll: collateral; HA: Hepatic artery; HVPG: Hepatic venous pressure gradient; IVC: Inferior vena cava; SSRs: Spontaneous splenorenal shunt.